Medical/Pharmaceuticals
InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of NMOSD in China
BEIJING, March 1, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the Investigational New Drug (IND) approval of its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib by China National Medical Products Administration (NMPA) to start ph...
2022-03-02 10:37
1766
WuXi Biologics Wins CMO Leadership Awards in All Six Core Categories for Fifth Consecutive Year
SHANGHAI, March 1, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMO service company, today announced that the company has won the 2022 CMO Leadership Awards in all six core categories (i.e., capabilities, compatibility, expertise, reliability, quality and service).2022 m...
2022-03-02 10:07
1727
Malaysian-Made ProDetect(R) Rapid Test-Kit Scores 100% Accuracy in International Assessment
GEORGE TOWN, Malaysia, March 2, 2022 /PRNewswire/ -- As the Omicron variant takes hold inMalaysia, the availability of high accuracy Antigen Test Kits is increasingly vital in the drive to identify infection early on and prevent further spread in the community. The ProDetect® COVID-19 Antigen Rap...
2022-03-02 09:15
2349
ImmVira's breakthrough intravenous oncolytic virus product MVR-T3011 IV completed first dosing in Phase I clinical trial in China
SHENZHEN, China, March 1, 2022 /PRNewswire/ -- Following its robust safety data in the U.S. Phase I clinical study, ImmVira announced that its global first intravenous administered oncolytic herpes simplex virus ("oHSV") product MVR-T3011 IV has completed first dosing onMarch 1, 2022 and initiate...
2022-03-02 09:07
1069
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications
SHANGHAI and HONG KONG, March 2, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer and other life...
2022-03-02 08:47
2421
Amrita University launch wearable device for home monitoring of glucose and BP
- Patients can use the wearable, non-invasive device to measure six body parameters including blood glucose, blood pressure, heart rate, blood oxygen, respiratory rate and 6-lead ECG, from the comfort of their home - The device, connected to the smart phone, can serve as a micro-bedside monitor ...
2022-03-02 07:40
1987
The Sigourney Trust Issues Call For Entries Of Psychoanalytic Work Eligible To Win The Sigourney Award-2022
Applications For The Sigourney Award-2022 Accepted March 1 Through July 31 SEATTLE, March 1, 2022 /PRNewswire/ -- Each year The Sigourney Trust honors up to four individuals, groups or organizations with an independent prize,The Sigourney Award. This prestigious international award honors recent...
2022-03-01 22:15
1546
Cambrex Expands Biopharmaceutical Services Business
EAST RUTHERFORD, N.J., March 1, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced it is significantly expanding its existing b...
2022-03-01 22:00
2224
Vocera, now part of Stryker, introduces latest evolution in hands-free communication to help protect and connect healthcare workers
New Minibadge expands intuitive mobile solutions for care team collaboration and safety KALAMAZOO, Michigan, USA, March 1, 2022 /PRNewswire/ -- Vocera, now part of Stryker, a global leading medical technology company, introduced the new Minibadge, a wearable, voice-driven device that enables mobi...
2022-03-01 21:00
1201
Kintor Pharma Announces First Patient Dosing in Phase II Clinical Trial of KX-826 for Treatment of Androgenic Alopecia Patients in the US
SUZHOU, China, March 1, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing in its phase II clinical trial of KX-826 ("...
2022-03-01 20:30
1649
Rare Disease Day | With iCare, Love is Not Rare, MediTrust Health - iCare Clover Gives Care and Protection to Rare Disease Patients
SHANGHAI, March 1, 2022 /PRNewswire/ -- "When Zixu was about 10 months old, he already seemed different from other children. He has curved fingers, a gradually bulging belly, and his intelligence also grows slowly," Zixu's mother calmly recounted the process of taking her child to seek medical tr...
2022-03-01 20:05
1349
Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Eight Additional European Countries
-- Ritonavir marketing authorization applications have been submitted to Spain, Portugal, Italy, Belgium, Poland, Sweden, the Netherlands and Denmark HANGZHOU, China and SHAOXING, China, March 1, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that it has submitted marketin...
2022-03-01 17:30
2271
Active agent in Australian-developed nasal spray >99.5% active against the Omicron SARS-CoV-2 variant
* The antiviral agent in VIRALEZE™ antiviral nasal spray, SPL7013, achieved >99.5% reduction of virus infectivity (the maximal possible reduction) against the highly contagious Omicron variant of SARS-CoV-2 * SPL7013 showed potent antiviral activity and was virucidal against the Omicron varia...
2022-03-01 16:44
1867
Terumo Establishes Group-wide 'DE&I Philosophy' to Further Cultivate a Diverse, Equitable and Inclusive Culture
TOKYO, Mar. 1, 2022 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced that it has established a global "DE&I Philosophy" to further cultivate the culture of Diversity, Equity, and Inclusion (DE&I) at the Terumo Group. Additionally, a "DE&I Guiding Principle" has also been defined to ...
2022-03-01 09:00
1849
Bangkok Dusit Medical Services embarks on sponsorship campaign with CNN focused on global health issues and healthy living
HONG KONG, March 1, 2022 /PRNewswire/ -- Bangkok Dusit Medical Services Public
Company Limited (BDMS), the largest healthcare network inThailand, is extending
its long-standing partnership with CNN International Commercial (CNNIC) with
the sponsorship of 'Vital Signs
2022-03-01 09:00
2344
Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, March 1, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2022-03-01 08:48
2492
Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2022
Added 18,985 New Subscribers in 3Q22 Revenues Up 9.1% YoY to RMB317.2 Million ($49.8 Million) Gross Profit Up 9.8% YoY to RMB269.9 Million ($42.4 Million) Operating Income Up 20.8% YoY to RMB149.7 Million ($23.5 Million) Non-GAAP Operating Income Up 18.6% YoY to RMB161.6 Million ($25.4 Mil...
2022-03-01 05:16
3087
Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
- NVX-CoV2373 demonstrates protection against symptomatic and asymptomatic infection - High level of vaccine efficacy maintained over a 6-month period of surveillance - Continued reassuring safety profile in line with previous trials GAITHERSBURG, Md., March 1, 2022 /PRNewswire/ -- Novavax, In...
2022-03-01 05:01
2462
MIM Software Inc. Announces Global Partnership with GenesisCare
CLEVELAND, Feb. 28, 2022 /PRNewswire/ -- MIM Software Inc. announced today a partnership with leading global provider of integrated cancer care, GenesisCare, to increase patient access to world-class care on a global scale. GenesisCare's clinical teams treat more than 400,000 patients at more tha...
2022-02-28 23:15
1332
Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
BENGALURU, India, Feb. 28, 2022 /PRNewswire/ -- Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), has entered into a definitive agreement with its partner Viatris Inc. (NASDAQ: VTRS). Accordingly, Biocon Biologics Ltd. (BBL) will acquire Viatris' biosimilars bus...
2022-02-28 22:15
2473
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 287 media titles]
2024-04-18 21:26
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 286 media titles]
2024-04-19 13:25
Animated Life in Yunnan
[Picked up by 281 media titles]
2024-04-18 14:00
Most Read
Combining Sustainability and Cybersecurity: Century Iron & Steel and Century Wind Power Both Receive ISO 27001 Information Security Certification
2024-04-19 18:03
9174
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
2024-04-18 21:26
8847
Animated Life in Yunnan
2024-04-18 14:00
7831
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
2024-04-19 13:25
7752